Momenta, Sandoz Settle Generic Lovenox Suit with Amphastar

By Emily Forster -

June 20, 2019

Momenta Pharmaceuticals, a biopharmaceutical company developing therapeutics for rare immune-mediated diseases and biosimilars, and Sandoz AG, the generics arm of Novartis, have settled litigation with Amphastar Pharmaceuticals, a specialty and generics company, resolving all pending litigation related to a generic version of Sanofi’s Lovenox (enoxaparin sodium injection), an anticoagulant.

Under the settlement, the parties jointly requested the US District Court for the District of Massachusetts vacate a 2017 patent judgement relating to both parties. The settlement became effective upon the District Court entering a final order vacating the patent judgement on June 18, 2019. Under the agreement, Momenta and Sandoz will pay Amphastar $59.9 million no later than July 2, 2019.

The parties dismissed the appeal of the 2017 patent judgment pending at the US Court of Appeals for the Federal Circuit and will submit stipulations of dismissal of all antitrust and patent cases pending in the District Court, according to Momenta and Amphastar.

Source: Momenta; Amphastar